The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases
Open accessAbstract
Protein arginine methyltransferases (PRMTs) play a crucial role in a variety of biological processes. Overexpression of PRMTs has been implicated in various human diseases including cancer. Consequently, selective small-molecule inhibitors of PRMTs have been pursued by both academia and the pharmaceutical industry as chemical tools for testing biological and therapeutic hypotheses. PRMTs are divided into three categories: type I PRMTs which catalyze mono- and asymmetric dimethylation of arginine residues, type II PRMTs which catalyze mono- and symmetric dimethylation of arginine residues, and type III PRMT which catalyzes only monomethylation of arginine residues. Here, we report the discovery of a potent, selective, and cell-active inhibitor of human type I PRMTs, MS023, and characterization of this inhibitor in a battery of biochemical, biophysical, and cellular assays. MS023 displayed high potency for type I PRMTs including PRMT1, -3, -4, -6, and -8 but was completely inactive against type II and type III PRMTs, protein lysine methyltransferases and DNA methyltransferases. A crystal structure of PRMT6 in complex with MS023 revealed that MS023 binds the substrate binding site. MS023 potently decreased cellular levels of histone arginine asymmetric dimethylation. It also reduced global levels of arginine asymmetric dimethylation and concurrently increased levels of arginine monomethylation and symmetric dimethylation in cells. We also developed MS094, a close analog of MS023, which was inactive in biochemical and cellular assays, as a negative control for chemical biology studies. MS023 and MS094 are useful chemical tools for investigating the role of type I PRMTs in health and disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein Arginine Methylation in Mammals: Who, What, and Why
Bedford, M. T., & Clarke, S. G. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.013 · Cited by 1,792
Bedford, M. T., & Richard, S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.003 · Cited by 1,099
Global histone modification patterns predict risk of prostate cancer recurrence
Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., & Kurdistani, S. K. (2005) · Nature · doi:10.1038/nature03672 · Cited by 1,092
Protein arginine methyltransferases and cancer
Yang, Y., & Bedford, M. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3409 · Cited by 1,083
Wang, H., Huang, Z.-Q., Xia, L., Feng, Q., Erdjument-Bromage, H., Strahl, B. D., Briggs, S. D., Allis, C. D., Wong, J., Tempst, P., et al. (2001) · Science · doi:10.1126/science.1060781 · Cited by 805
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
Chan-Penebre, E., Kuplast, K. G., Majer, C. R., Boriack-Sjodin, P. A., Wigle, T. J., Johnston, L. D., Rioux, N., Munchhof, M. J., Jin, L., Jacques, S. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1810 · Cited by 569
Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive
Guccione, E., Bassi, C., Casadio, F., Martinato, F., Cesaroni, M., Schuchlautz, H., Lüscher, B., & Amati, B. (2007) · Nature · doi:10.1038/nature06166 · Cited by 491
Strahl, B. D., Briggs, S. D., Brame, C. J., Caldwell, J. A., Koh, S. S., Ma, H., Cook, R. G., Shabanowitz, J., Hunt, D. F., Stallcup, M. R., et al. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00294-9 · Cited by 453
Frye, S. V. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.296 · Cited by 375
Cer, R. Z., Mudunuri, U., Stephens, R., & Lebeda, F. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp253 · Cited by 367
Yoshimatsu, M., Toyokawa, G., Hayami, S., Unoki, M., Tsunoda, T., Field, H. I., Kelly, J. D., Neal, D. E., Maehara, Y., Ponder, B. A. J., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25366 · Cited by 313
Deciphering arginine methylation: Tudor tells the tale
Chen, C., Nott, T. J., Jin, J., & Pawson, T. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3185 · Cited by 301
Self-citationCARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis
Wang, L., Zhao, Z., Meyer, M. B., Saha, S., Yu, M., Guo, A., Wisinski, K. B., Huang, W., Cai, W., Pike, J. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.007 · Cited by 264
PRMT9 is a Type II methyltransferase that methylates the splicing factor SAP145
Yang, Y., Hadjikyriacou, A., Xia, Z., Gayatri, S., Kim, D., Zurita-Lopez, C., Kelly, R., Guo, A., Li, W., Clarke, S. G., et al. (2015) · Nature Communications · doi:10.1038/ncomms7428 · Cited by 235
Loss of the major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs
Dhar, S., Vemulapalli, V., Patananan, A. N., Huang, G. L., Di Lorenzo, A., Richard, S., Comb, M. J., Guo, A., Clarke, S. G., & Bedford, M. T. (2013) · Scientific Reports · doi:10.1038/srep01311 · Cited by 228
Hong, H., Kao, C., Jeng, M., Eble, J. N., Koch, M. O., Gardner, T. A., Zhang, S., Li, L., Pan, C., Hu, Z., et al. (2004) · Cancer · doi:10.1002/cncr.20327 · Cited by 204
Tripsianes, K., Madl, T., Machyna, M., Fessas, D., Englbrecht, C., Fischer, U., Neugebauer, K. M., & Sattler, M. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2185 · Cited by 201
PRMT5 is required for cell-cycle progression and p53 tumor suppressor function
Scoumanne, A., Zhang, J., & Chen, X. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp516 · Cited by 194
Protein arginine methylation of non-histone proteins and its role in diseases
Wei, H., Mundade, R., Lange, K., & Lu, T. (2014) · Cell Cycle · doi:10.4161/cc.27353 · Cited by 190
( R )-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells
Barsyte-Lovejoy, D., Li, F., Oudhoff, M. J., Tatlock, J. H., Dong, A., Zeng, H., Wu, H., Freeman, S. A., Schapira, M., Senisterra, G. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407358111 · Cited by 185
Self-citationKanıskan, H. Ü., Szewczyk, M. M., Yu, Z., Eram, M. S., Yang, X., Schmidt, K. T., Luo, X., Dai, M., He, F., Zang, I., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201412154 · Cited by 148
Self-citationRole of the PRMT–DDAH–ADMA axis in the regulation of endothelial nitric oxide production
Pope, A. J., Karuppiah, K. M., & Cardounel, A. J. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.07.016 · Cited by 141
Selective Inhibitors of Protein Methyltransferases
Kanıskan, H. Ü., Konze, K. D., & Jin, J. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501234a · Cited by 137
Self-citationThe PRMT1 gene expression pattern in colon cancer
Mathioudaki, K., Παπαδοκωστοπούλου, Α., Scorilas, A., Xynopoulos, D., Agnanti, N., & Talieri, M. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604807 · Cited by 136
Differential CARM1 expression in prostate and colorectal cancers
Kim, Y.-R., Lee, B. K., Park, R., NGUYEN, N. T. X., Bae, J. A., Kwon, D. D., & Jung, C. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-197 · Cited by 134
Non‐Competitive Inhibition by Active Site Binders
Blat, Y. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.00972.x · Cited by 127
Shia, W.-J., Okumura, A. J., Yan, M., Sarkeshik, A., Lo, M., Matsuura, S., Komeno, Y., Zhao, X., Nimer, S. D., Yates, J. R., et al. (2012) · Blood · doi:10.1182/blood-2011-04-347476 · Cited by 124
Structural basis for CARM1 inhibition by indole and pyrazole inhibitors
Sack, J. S., Thieffine, S., Bandiera, T., Fasolini, M., Duke, G. J., Jayaraman, L., Kish, K., Klei, H. E., Purandare, A. V., Rosettani, P., et al. (2011) · Biochemical Journal · doi:10.1042/bj20102161 · Cited by 109
p53-Independent regulation of p21Waf1/Cip1 expression and senescence by PRMT6
Phalke, S., Mzoughi, S., Bezzi, M., Jennifer, N., Mok, W. C., Low, D. H. P., Thike, A. A., Kuznetsov, V. A., Tan, P. H., Voorhoeve, P. M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks858 · Cited by 107
Deregulated expression of selected histone methylases and demethylases in prostate carcinoma
Vieira, F. Q., Costa‐Pinheiro, P., Ramalho-Carvalho, J., Faria‐Pereira, A., Menezes, F. D., Antunes, L., Carneiro, I. C., Oliveira, J., Henrique, R., & Jerónimo, C. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0375 · Cited by 103
An Allosteric Inhibitor of Protein Arginine Methyltransferase 3
Siarheyeva, A., Senisterra, G. A., Allali‐Hassani, A., Dong, A., Dobrovetsky, E., Wasney, G. A., Chau, I., Marcellus, R. C., Hajian, T., Liu, F., et al. (2012) · Structure · doi:10.1016/j.str.2012.06.001 · Cited by 102
Self-citationDiscovery of a Dual PRMT5–PRMT7 Inhibitor
Smil, D. V., Eram, M. S., Li, F., Kennedy, S., Szewczyk, M. M., Brown, P. J., Baršytė-Lovejoy, D., Arrowsmith, C. H., Vedadi, M., & Schapira, M. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500467h · Cited by 99
Self-citationPyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1)
Purandare, A. V., Chen, Z., Huynh, T., Pang, S., Geng, J., Vaccaro, W. D., Poss, M. A., O’Connell, J. C., Nowak, K., & Jayaraman, L. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.06.026 · Cited by 97
Stein, C., Riedl, S., Rüthnick, D., Nötzold, R. R., & Bauer, U. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks767 · Cited by 97
Allan, M., Manku, S., Therrien, É., Nguyen, N. N. M., Styhler, S., Robert, M., Goulet, A.-C., Petschner, A. J., Rahil, G., MacLeod, A. R., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.075 · Cited by 94
Mitchell, L. H., Boriack-Sjodin, P. A., Smith, S., Thomenius, M., Rioux, N., Munchhof, M., Mills, J. E., Klaus, C., Totman, J., Riera, T. V., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00272 · Cited by 91
Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)
Huynh, T., Chen, Z., Pang, S., Geng, J., Bandiera, T., Bindi, S., Vianello, P., Roletto, F., Thieffine, S., Galvani, A. P., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.075 · Cited by 88
Baldwin, R. M., Morettin, A., Paris, G., Goulet, I., & Côté, J. (2012) · Cell Cycle · doi:10.4161/cc.22871 · Cited by 80
Exploiting an Allosteric Binding Site of PRMT3 Yields Potent and Selective Inhibitors
Liu, F., Li, F., Ma, A., Dobrovetsky, E., Dong, A., Gao, C., Korboukh, I., Liu, J., Smil, D. V., Brown, P. J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3018332 · Cited by 80
Self-citationCARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features
Akoum, R. E., Gauchotte, G., Oussalah, A., Wissler, M.-P., Clément-Duchêne, C., Vignaud, J.-M., Guéant, J., & Namour, F. (2013) · Biochimie · doi:10.1016/j.biochi.2013.10.021 · Cited by 78
Arginine methyltransferase CARM1/PRMT4 regulates endochondral ossification
Ito, T., Yadav, N., Lee, J. H., Furumatsu, T., Yamashita, S., Yoshida, K., Taniguchi, N., Hashimoto, M., Tsuchiya, M., Ozaki, T., et al. (2009) · BMC Developmental Biology · doi:10.1186/1471-213x-9-47 · Cited by 73
Castellano, S., Milite, C., Ragno, R., Simeoni, S., Mai, A., Limongelli, V., Novellino, E., Bauer, I., Brosch, G., Spannhoff, A., et al. (2010) · ChemMedChem · doi:10.1002/cmdc.200900459 · Cited by 72
Wan, H., Huynh, T., Pang, S., Geng, J., Vaccaro, W. D., Poss, M. A., Trainor, G. L., Lorenzi, M. V., Gottardis, M. M., Jayaraman, L., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.07.040 · Cited by 68
Chemical Probes of Histone Lysine Methyltransferases
Kanıskan, H. Ü., & Jin, J. J. (2014) · ACS Chemical Biology · doi:10.1021/cb500785t · Cited by 65
Self-citationDeregulation of protein methylation in melanoma
Limm, K., Ott, C., Wallner, S., Mueller, D. W., Oefner, P. J., Hellerbrand, C., & Bosserhoff, A. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.026 · Cited by 63
1,2-Diamines as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1)
Therrien, É., Larouche, G., Manku, S., Allan, M., Nguyen, N. N. M., Styhler, S., Robert, M., Goulet, A.-C., Besterman, J. M., Nguyen, H., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.110 · Cited by 56
DDAH gene and cardiovascular risk
Valkonen, V.-P., Tuomainen, T., & Laaksonen, R. (2005) · Vascular Medicine · doi:10.1191/1358863x05vm600oa · Cited by 48
The role of protein arginine-methyltransferase 1 in gliomagenesis
Wang, S., Tan, X., Yang, B., Yin, B., Yuan, J.-G., Qiang, B., & Peng, X. (2012) · BMB Reports · doi:10.5483/bmbrep.2012.45.8.022 · Cited by 47
Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension
Landburg, P. P., Teerlink, T., van Beers, E. J., Muskiet, F. A. J., Kappers‐Klunne, M. C., van Esser, J. W. J., Gillavry, M. R. M., Biemond, B. J., Brandjes, D. P. M., Duits, A. J., et al. (2008) · Haematologica · doi:10.3324/haematol.12928 · Cited by 25
Cited by
Arginine Methylation: The Coming of Age
Blanc, R. S., & Richard, S. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.11.003 · Cited by 1,054
The regulation, functions and clinical relevance of arginine methylation
Guccione, E., & Richard, S. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0155-x · Cited by 625
Amino acid metabolism in health and disease
Ling, Z.-N., Jiang, Y.-F., Ru, J.-N., Lu, J.-H., Ding, B., & Wu, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01569-3 · Cited by 545
Protein arginine methylation: from enigmatic functions to therapeutic targeting
Wu, Q., Schapira, M., Arrowsmith, C. H., & Barsyte-Lovejoy, D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00159-8 · Cited by 419
Self-citationEpigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy
Biswas, S., & Rao, C. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.021 · Cited by 389
Metadata
- Authors
- Eram, M. S., Shen, Y., Szewczyk, M. M., Wu, H., Senisterra, G., Li, F., Butler, K. V., Kaniskan, H. Ü., Speed, B. A., dela Seña, C., Dong, A., Zeng, H., Schapira, M., Brown, P. J., Arrowsmith, C. H., Barsyte-Lovejoy, D., Liu, J., Vedadi, M., & Jin, J.
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-12-08
- Volume
- 11
- Issue
- 3
- Pages
- 772-781
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- OpenAlex
- W2331846333
- Cited by
- 289
- References
- 49
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.